2 High-Yield Dividend Stocks to Buy and 1 to Avoid

The article favors Energy Transfer and Verizon as high-yield investments while warning that Pfizer's 6.2% dividend faces cash-flow, debt, and patent-expiry risks. Pfizer paid $9.7B in dividends against $9.1B in free cash flow last year and carries more than $60B of debt following its $43B Seagen acquisition. Energy Transfer yields 6.4%, targets 3%-5% annual distribution growth, plans up to $5.9B of growth capex, and trades at 8.5x forward EV/EBITDA; Verizon yields 5.5% and added 184,000 postpaid phone subscribers, its best quarter in five years.

Analysis

The actionable signal is not headline yield but capital-allocation flexibility. PFE’s oncology acquisition must now offset both forthcoming loss-of-exclusivity pressure and elevated financing costs; absent faster deleveraging, management’s long-dated growth target has limited credibility and the equity risks becoming a yield trap. The relevant near-term catalyst is any reduction in forward EPS/FCF estimates or an explicit shift in dividend language; a successful late-stage oncology readout or asset-sale-driven debt reduction would falsify the short thesis.

ET’s data-center linkage is directionally valid but should be separated from actual contracted volumes. The strongest earnings sensitivity is likely in Texas intrastate transport, processing and power-related gas infrastructure rather than a generalized national AI-demand thesis; project backlog conversion and returns on growth capital matter more than spot gas. Over 6-18 months, incremental gas-fired generation demand could tighten regional basis and expand ET’s opportunity set, but a capex overrun, weak project contracting, or a lower-return acquisition would negate the valuation discount.

VZ has a cleaner 1-3 month setup than its yield peers if churn improvement translates into service-revenue and EBITDA guidance upside. The underappreciated offset is that fiber expansion raises both bundling optionality and integration/capital-intensity risk: Frontier synergies must exceed incremental interest, build, and customer-acquisition costs before the multiple can rerate. Consensus may be too quick to annualize one strong subscriber quarter, making subsequent churn and wireless service-revenue trends the key confirmation points.

Key Decisions for Investors

• Initiate a 3-6 month long ET / short PFE pair, sized beta-neutral: ET has contracted-growth and regional power-demand optionality, while PFE faces asymmetric downside if 2027-28 FCF or dividend expectations reset. Target 10-15% relative return; exit if ET’s project-return disclosures weaken or PFE delivers credible debt reduction plus pipeline upside.
• Buy VZ on confirmation of a second consecutive quarter of improving postpaid churn and maintained wireless service-revenue guidance; use a 6-12 month horizon. Upside is a modest rerating from earnings durability and fiber synergies, while stop/reassess on churn reversal, Frontier integration-cost escalation, or higher capex guidance.
• Avoid adding PFE solely for income until quarterly FCF covers dividends after interest and restructuring cash costs. Set an alert for any dividend-policy revision, downward 2027-28 revenue guidance, or oncology trial failure; those events would likely drive a faster multiple reset than current yield pricing implies.
• For ET, monitor announced data-center or power-generation contracts in Texas and capex-to-EBITDA conversion rather than AI rhetoric. Add only after evidence that new projects are substantially committed and leverage remains within management targets; this is the key distinction between sustainable distribution growth and externally financed expansion.